Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma

PURPOSE: To explore the efficacy and safety of TQB2450 combined with anlotinib in patients with locally advanced or metastatic soft-tissue sarcoma (LA/M STS). PATIENTS AND METHODS: This was a single arm phase II study (TQB2450-Ib-02 study) performed at two hospitals in China to assess the potency of...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jiayong, Gao, Tian, Tan, Zhichao, Li, Shu, Xu, Jie, Bai, Chujie, Xue, Ruifeng, Xie, Lu, Zhang, Lu, Fan, Zhengfu, Guo, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662895/
https://www.ncbi.nlm.nih.gov/pubmed/35675031
http://dx.doi.org/10.1158/1078-0432.CCR-22-0871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662895/
https://www.ncbi.nlm.nih.gov/pubmed/35675031
http://dx.doi.org/10.1158/1078-0432.CCR-22-0871

Ejemplares similares